A 62-year-old man presents to the clinic for a routine follow-up. He has a history of end-… — USMLE Step 3

A $62$ -year-old man presents to the clinic for a routine follow-up. He has a history of end-stage renal disease (ESRD) requiring hemodialysis three times a week, as well as diet-controlled type $2$ diabetes mellitus. Two weeks ago, the patient was hospitalized for a generalized tonic-clonic seizure, which was successfully treated. He was discharged on a maintenance regimen of oral phenytoin $300$ mg daily. Since discharge, he has had no further seizure activity and reports no side effects such as dizziness or unsteadiness.

Vital signs are within normal limits. Neurological examination reveals no nystagmus, normal tandem gait, and an intact Mini-Mental State Examination.

Recent laboratory studies reveal the following:

Test	Result	Reference Range
Blood urea nitrogen	$72$ mg/dL	$7$ - $20$ mg/dL
Serum creatinine	$6.8$ mg/dL	$0.6$ - $1.2$ mg/dL
Serum albumin	$2.5$ g/dL	$3.5$ - $5.0$ g/dL
Total serum phenytoin	$4.5$ $\mu$ g/mL	$10$ - $20$ $\mu$ g/mL

Based on these findings, which of the following is the most appropriate next step in management?

Continue the current phenytoin dosage and monitor the patient clinicallyCevap
B
Increase the daily phenytoin dosage to target a total serum concentration of $10$ - $20$ $\mu$ g/mL
C
Schedule the phenytoin administration strictly after hemodialysis sessions
D
Measure a peak total serum phenytoin concentration two hours after the next dose
E
Add a second antiepileptic drug due to therapeutic failure of monotherapy

Cevap

Continue the current phenytoin dosage and monitor the patient clinically.

The correct management is to continue the current dosage and monitor the patient clinically. Phenytoin is a highly lipophilic antiepileptic drug that is extensively bound to plasma albumin (approximately

90\%

in healthy individuals). In patients with end-stage renal disease and hypoalbuminemia, the protein binding of phenytoin is significantly reduced. This occurs due to a combination of decreased available albumin molecules and competition for remaining binding sites by accumulated uremic toxins. Consequently, the fraction of unbound (free) phenytoin—which is the pharmacologically active form capable of crossing the blood-brain barrier—drastically increases. Because standard laboratory assays measure total (bound plus free) serum phenytoin, the reported total concentration will appear artificially low (

4.5

\mu

g/mL) even when the free drug concentration is highly therapeutic. The patient's actual adjusted total phenytoin level can be estimated using the Sheiner-Tozer formula for ESRD, which reveals that his active drug exposure is equivalent to a normal patient with a therapeutic total level. Given that the patient is clinically stable, seizure-free, and exhibiting no signs of toxicity, the current regimen is effective and should be maintained.

Adım Adım Çözüm

Evaluate the patient's clinical status alongside the isolated laboratory abnormality.

The patient is seizure-free and asymptomatic without signs of toxicity, yet has a seemingly subtherapeutic total phenytoin level of

4.5

\mu

g/mL.

Clinical context must always dictate the interpretation of therapeutic drug monitoring, especially in the presence of severe comorbidities.

Analyze the pharmacokinetic properties of the prescribed drug in relation to the patient's comorbidities.

Phenytoin is highly bound to serum albumin. The patient has ESRD (causing uremia) and significant hypoalbuminemia (

2.5

g/dL).

Uremic toxins compete for albumin binding sites, and a low absolute albumin level provides fewer binding sites overall, significantly disrupting normal pharmacokinetics.

Determine the downstream effect of decreased protein binding on the drug's activity.

The unbound (free) fraction of phenytoin increases. Because standard assays measure total (bound + free) drug, the reported total concentration appears artificially low, even though the free (active) concentration is therapeutic.

Only the unbound drug can cross the blood-brain barrier to exert antiepileptic effects and dictate toxicity.

Select the most appropriate management based on combined clinical and pharmacokinetic data.

Because the patient is clinically stable and the free drug level is presumably in the target range, no dose adjustment is required.

Increasing the dose to normalize the total level would cause severe neurotoxicity.

Anahtar Kavram

Pharmacokinetic alterations of highly protein-bound drugs in end-stage renal disease and hypoalbuminemia.

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru